Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer....
Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence...
Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast...
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be...
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant...
Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing...
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation...
Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib...
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.